You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
SBC: Syntrix Biosystems, Inc. Topic: 102Prostate cancer (PC) is the second leading cause of cancer-related death among American men, and the vast majority of these deaths are due to metastatic, castration-resistant PC (mCRPC). Androgen suppression therapy (AST) is used to treat PC patients, which comprise of: (1) androgen deprivation therapy (ADT) with LHRH agonists or antagonists; (2) blocking CYP17-mediated androgen synthesis with abi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Commercialization Readiness for Nerve Tape: a nerve repair coaptation aid
SBC: BIOCIRCUIT TECHNOLOGIES INC Topic: NINDSProject Summary This SBIR Commercialization Readiness Pilot project will prepare and achieve the commercial launch of Bio- Circuit Technologies’ Nerve Tape® device for sutureless nerve repair. Nerve injuries are common and result in paralysis, sensory loss, and chronic pain. In current repair techniques, the ends of a cut nerve are microsutured back together under high magnification by a specia ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development and clinical assessment of a robust, 3D printed titanium, myoelectric powered prosthetic digit system
SBC: POINT DESIGNS, LLC Topic: 106ABSTRACT Approximately 600,000 people live with partial hand amputations in the United States, with an estimated 14,500 new cases occurring each year. Despite the advances in miniaturized electronics and motors, there has been very little advancement in mechatronic prosthetic digits for this underserved patient population. In fact, to date, there is only one myoelectric prosthetic option for patie ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine
SBC: ORLANCE, INC Topic: NIAIDPROJECT SUMMARY Orlance has developed a lead universal influenza (UFlu) DNA vaccine to address the need for a vaccine that can protect from annual influenza and the emergence of new variants that could cause future pandemics. Our UFlu vaccine is a multi-dose vaccine designed to induce systemic and mucosal immune responses that can prevent transmission and minimize disease from currently circulatin ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing
SBC: TWINSTRAND BIOSCIENCES INC Topic: NCIProblem: With a 5-year survival of ~30%, AML is the 6th deadliest cancer, and rt20,000 new patients are diagnosed each year in the United States. Although most patients achieve Complete Remission (CR) with aggressive therapy, most will eventually relapse. The criteria for CR, however, is based on historical diagnostic methods, and patients in CR may carry up to 1010 residual leukemia blasts. Signi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Comparative testing of tatCN19o for neuroprotection in rodent tMCAo
SBC: NEUREXIS THERAPEUTICS, INC. Topic: NINDSProject Summary/Abstract Focal cerebral ischemia (stroke) afflicts nearly 800,000 Americans each year and often results in permanent cognitive impairment or death. Efforts in developing a cerebroprotective stroke therapy have largely resulted in disappointment: the only approved pharmacological therapy is hemolytic treatment with tissue plasminogen activator (tPA; alteplase). In this project, we w ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Spinal Reflex Conditioning System for Enhancing Motor Function Recovery After Incomplete Spinal Cord Injury
SBC: BIOCIRCUIT TECHNOLOGIES INC Topic: 999Project Summary Spinal Cord Injury (SCI) affects ~300,000 people in the US, with 11,000 new cases/year. After SCI, spinal reflex function becomes abnormal, contributing to motor impairments and spasticity that affects 65-78% of people with SCI. Thus, restoring the function of spinal reflex pathways is a major therapeutic goal. Current therapies are only moderately successful; motor function often ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias
SBC: HEMEX HEALTH INC Topic: NHLBIPROJECT SUMMARY Anemia is characterized by low blood hemoglobin levels and has a high prevalence, affecting over one-third of the world's population of about 2.5 billion people. More than 7% of the world’s population carry hemoglobin gene mutations that result in hemoglobin variants, one of which is Sickle Cell Disease (SCD). SCD impacts about 100,000 Americans. The trait form of SCD is the Sick ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development and testing of a digitally assisted risk reduction platform for youth at high risk for suicide
SBC: KSANA HEALTH INC Topic: 104ABSTRACTDespite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Although promising approaches are available for preventative interventions with youth at-risk for suicide, they demonstrate modest benefit, and recent reviews have concluded that new developments are required that facilitate not only greater effectiveness, but also enh ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Disseminable Evidence-Based Treatment for the Dental Office: Virtual Exposure Tools for Dental Fear- neVR Fear the Dentist
SBC: VIRTUALLY BETTER INC Topic: NIDCRPROJECT SUMMARY/ABSTRACTEach year over 20 million adults with moderate fear and over 14 million adults with severe fear visit the dentist. Because fear portends poor future oral health, patients with dental fear come to experience their worst fears: pain, surgical procedures, and the need for more frequent dental visits. Avoidance is the natural and reinforced response, ironically guaranteeing a r ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health